Skip to Main content Skip to Navigation
Master Thesis

Bendamustine-Etoposide-Cytarabine-Melphalan (BeEAM) versus Carmustine-Etoposide-Cytarabine-Melphalan (BEAM) chez les patients atteints de lymphome à cellules du manteau traités par autogreffe en première ligne : étude comparative rétrospective multicentrique des centres du Lymphoma Study Association (LYSA)

Abstract : The combination of carmustine, etoposide, cytarabine, and melphalan (BEAM) as conditioning regimen prior to autologous stem-cell transplantation (ASCT) remains the standard of care for patients with mantle cell lymphoma (MCL) who are eligible for transplantation. The replacement of carmustine with bendamustine (BeEAM) was recently described as a promising alternative in non-Hodgkin lymphoma. The aim of this retrospective study was to compare the BeEAM to the BEAM regimens in MCL patients in the frontline setting. Sixty and 108 patients were included in the BeEAM and the BEAM groups, respectively. At 3 years, progression-free survival (PFS) was significantly higher in the BeEAM than in the BEAM group (84% [73-96] vs. 63% [51-79]; p=0.03). However, the overall survival was not statistically different between the two groups (p=0.2). According to multivariable analysis, BeEAM regimen remained associated with a higher PFS (HR=0.377 95% CI, 0.146-0.970; p=0.043). Subgroup analyses in patients treated with prior R-aracytine induction alone showed that BeEAM improved the PFS compared to the BEAM regimen (84% [71-100] vs. 55% [24100]; p=0.04). In patients without rituximab maintenance, there was a trend toward a higher PFS with BeEAM compared to BEAM (80% [65-98] vs. 63 [50-79]; p=0.07). The treatment related mortality was not increased with the BeEAM regimen. This retrospective study suggests that the BeEAM regimen is effective and could be considered as an alternative to the BEAM regimen in MCL patients undergoing ASCT.
Document type :
Master Thesis
Complete list of metadatas

Cited literature [35 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-02466065
Contributor : Ufr Santé Unicaen <>
Submitted on : Tuesday, February 4, 2020 - 11:48:29 AM
Last modification on : Friday, October 23, 2020 - 4:57:49 PM

Identifiers

  • HAL Id : dumas-02466065, version 1

Citation

Thomas Hueso. Bendamustine-Etoposide-Cytarabine-Melphalan (BeEAM) versus Carmustine-Etoposide-Cytarabine-Melphalan (BEAM) chez les patients atteints de lymphome à cellules du manteau traités par autogreffe en première ligne : étude comparative rétrospective multicentrique des centres du Lymphoma Study Association (LYSA). Médecine humaine et pathologie. 2019. ⟨dumas-02466065⟩

Share

Metrics

Record views

14

Files downloads

32